Prothena Net Income 2011-2022 | PRTA

Prothena net income from 2011 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Prothena Annual Net Income
(Millions of US $)
2021 $67
2020 $-111
2019 $-78
2018 $-156
2017 $-153
2016 $-160
2015 $-81
2014 $-7
2013 $-41
2012 $-41
2011 $-30
2010 $-12
Prothena Quarterly Net Income
(Millions of US $)
2022-03-31 $-36
2021-12-31 $-33
2021-09-30 $109
2021-06-30 $28
2021-03-31 $-37
2020-12-31 $-31
2020-09-30 $-31
2020-06-30 $-26
2020-03-31 $-24
2019-12-31 $-22
2019-09-30 $-19
2019-06-30 $-16
2019-03-31 $-21
2018-12-31 $-22
2018-09-30 $-25
2018-06-30 $-60
2018-03-31 $-49
2017-12-31 $-48
2017-09-30 $-52
2017-06-30 $-18
2017-03-31 $-35
2016-12-31 $-49
2016-09-30 $-43
2016-06-30 $-40
2016-03-31 $-28
2015-12-31 $-24
2015-09-30 $-23
2015-06-30 $-18
2015-03-31 $-15
2014-12-31 $-13
2014-09-30 $-13
2014-06-30 $1
2014-03-31 $18
2013-12-31 $-11
2013-09-30 $-10
2013-06-30 $-11
2013-03-31 $-9
2012-12-31 $-12
2012-09-30 $-9
2012-06-30 $-10
2012-03-31 $-11
2011-12-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.205B $0.201B
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.449B 10.01
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.298B 16.25
Biohaven Pharmaceutical Holding (BHVN) United States $10.114B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.068B 0.00
Emergent Biosolutions (EBS) United States $1.695B 7.26
Arcus Biosciences (RCUS) United States $1.307B 33.13
Myovant Sciences (MYOV) United Kingdom $0.933B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.493B 0.00
Gelesis Holdings (GLS) United States $0.348B 0.00
Zymeworks (ZYME) Canada $0.342B 0.00
Ambrx Biopharma (AMAM) United States $0.162B 0.00
Enzo Biochem (ENZ) United States $0.112B 23.00
SQZ Biotechnologies (SQZ) United States $0.094B 0.00